Springer Science and Business Media LLC
Safety and Efficacy of Hizentra ® Following Pediatric Hematopoietic Cell Transplant for Treatment of Primary Immunodeficiencies
Preprints
Patel, NC; Torgerson, T; Thakar, M; Younger, EM; Sriar, P; Pozos, T; Buckley, R; Morris, D; Vilkama, D; Heimall, J
November 7, 2022
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Citation
APA
Chicago
ICMJE
MLA
NLM
Patel, N. C., Torgerson, T., Thakar, M., Younger, E. M., Sriar, P., Pozos, T., … Heimall, J. (2022). Safety and Efficacy of Hizentra ® Following Pediatric Hematopoietic Cell Transplant for Treatment of Primary Immunodeficiencies. Springer Science and Business Media LLC. https://doi.org/10.21203/rs.3.rs-2216817/v1
Patel, Niraj C., Troy Torgerson, Monika Thakar, Elizabeth M. Younger, Panida Sriar, Tamara Pozos, Rebecca Buckley, David Morris, Diana Vilkama, and Jennifer Heimall. “Safety and Efficacy of Hizentra ® Following Pediatric Hematopoietic Cell Transplant for Treatment of Primary Immunodeficiencies.” Springer Science and Business Media LLC, November 7, 2022. https://doi.org/10.21203/rs.3.rs-2216817/v1.
Patel NC, Torgerson T, Thakar M, Younger EM, Sriar P, Pozos T, et al. Safety and Efficacy of Hizentra ® Following Pediatric Hematopoietic Cell Transplant for Treatment of Primary Immunodeficiencies. Springer Science and Business Media LLC. 2022.
Patel, Niraj C., et al. “Safety and Efficacy of Hizentra ® Following Pediatric Hematopoietic Cell Transplant for Treatment of Primary Immunodeficiencies.” Springer Science and Business Media LLC, 7 Nov. 2022. Crossref, doi:10.21203/rs.3.rs-2216817/v1.
Patel NC, Torgerson T, Thakar M, Younger EM, Sriar P, Pozos T, Buckley R, Morris D, Vilkama D, Heimall J. Safety and Efficacy of Hizentra ® Following Pediatric Hematopoietic Cell Transplant for Treatment of Primary Immunodeficiencies. Springer Science and Business Media LLC. 2022.